Jubilant Pharmova Limited has informed the Exchange about Schedule of meet and Presentation
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jubilant Pharmova has informed the exchanges that its management will hold one-on-one and group meetings with 9 institutional investors on August 6, 2025, in Singapore, organized as part of Nuvama Institutional Equities' India Conference. Investors include Lion Global Investor, Tree Line Investment Management, Indea Capital, Persistence Capital, Templeton Emerging Markets Group, Amansa Investment Advisors, Ward Ferry Management, Millennium Partners, and Capital Research. Along with the intimation, the company shared its July 2025 investor presentation. The presentation highlights Q1 FY26 total revenue of Rs. 1,901 Cr (+10% YoY), EBITDA of Rs. 302 Cr (+14% YoY) at 15.8% margin, and Normalised PAT of Rs. 103 Cr (+48% YoY). Net debt stands at Rs. 1,535 Cr with Net Debt/EBITDA at 1.2x. The company reiterated its FY30 vision of doubling revenue to Rs. 13,500 Cr, achieving 23–25% EBITDA margins, zero net debt, and high-teens RoCE.
This is a routine investor engagement filing, but the inclusion of marquee global investors (Templeton, Capital Research, Millennium) signals ongoing institutional interest. Sustained outreach and the detailed presentation may improve foreign investor visibility, though near-term stock impact is likely limited since no material new disclosures were made beyond Q1 FY26 numbers already known.